These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39448057)

  • 1. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
    Sands BE; D'Haens G; Clemow DB; Irving PM; Johns JT; Gibble TH; Abreu MT; Lee SD; Hisamatsu T; Kobayashi T; Dubinsky MC; Vermeire S; Siegel CA; Peyrin-Biroulet L; Moses RE; Milata J; Panaccione R; Dignass A
    Inflamm Bowel Dis; 2024 Oct; ():. PubMed ID: 39448057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
    Sands BE; D'Haens G; Clemow DB; Irving PM; Johns JT; Hunter Gibble T; Abreu MT; Lee S; Hisamatsu T; Kobayashi T; Dubinsky MC; Vermeire S; Siegel CA; Peyrin-Biroulet L; Moses RE; Milata J; Arora V; Panaccione R; Dignass A
    Inflamm Bowel Dis; 2024 Dec; 30(12):2245-2258. PubMed ID: 38459910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.
    Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L
    J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme.
    Danese S; Dignass A; Matsuoka K; Ferrante M; Long M; Redondo I; Moses R; Maier S; Hunter Gibble T; Morris N; Milch C; Abreu MT
    J Crohns Colitis; 2024 Nov; 18(11):1845-1856. PubMed ID: 38869019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
    N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies.
    Long MD; Schreiber S; Hibi T; Gibble TH; Fisher DA; Park G; Moses RE; Higgins PDR; Lindsay JO; Lee SD; Escobar R; Jairath V
    Crohns Colitis 360; 2024 Jan; 6(1):otae001. PubMed ID: 38313767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
    Dubinsky MC; Clemow DB; Hunter Gibble T; Li X; Vermeire S; Hisamatsu T; Travis SPL
    Crohns Colitis 360; 2023 Jan; 5(1):otac044. PubMed ID: 36777368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
    Kobayashi T; Matsuoka K; Watanabe M; Hisamatsu T; Hirai F; Milata J; Li X; Morris N; Arora V; Ishizuka T; Matsuo K; Satoi Y; Milch C; Hibi T
    Intest Res; 2024 Apr; 22(2):172-185. PubMed ID: 38720466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
    Sands BE; Feagan BG; Hunter Gibble T; Traxler KA; Morris N; Eastman WJ; Schreiber S; Jairath V; Long MD; Armuzzi A
    Crohns Colitis 360; 2023 Oct; 5(4):otad070. PubMed ID: 38034882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
    D'Haens G; Higgins PDR; Peyrin-Biroulet L; Sands BE; Lee S; Moses RE; Redondo I; Escobar R; Hunter Gibble T; Keohane A; Morris N; Zhang X; Arora V; Kobayashi T
    Inflamm Bowel Dis; 2024 Dec; 30(12):2335-2346. PubMed ID: 38271613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
    Choi D; Sheridan H; Bhat S
    Ann Pharmacother; 2024 Nov; 58(11):1134-1139. PubMed ID: 38344998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies.
    Friedrich S; Chua L; Adams DH; Crandall W; Zhang XC
    Clin Pharmacol Ther; 2024 Aug; 116(2):435-447. PubMed ID: 38797892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
    Sands BE; Peyrin-Biroulet L; Kierkus J; Higgins PDR; Fischer M; Jairath V; Hirai F; D'Haens G; Belin RM; Miller D; Gomez-Valderas E; Naegeli AN; Tuttle JL; Pollack PF; Sandborn WJ
    Gastroenterology; 2022 Feb; 162(2):495-508. PubMed ID: 34748774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis.
    Moćko P; Koperny M; Śladowska K; Holko P; Kowalska-Bobko I; Kawalec P
    Pharmacotherapy; 2024 Oct; 44(10):811-821. PubMed ID: 39320112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52.
    Johnson T; Steere B; Zhang P; Zang Y; Higgs R; Milch C; Reinisch W; Panés J; Huang K; D'Haens G; Krishnan V
    Clin Transl Gastroenterol; 2023 Nov; 14(11):e00630. PubMed ID: 37594044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
    Parkes G; Ungaro RC; Danese S; Abreu MT; Arenson E; Zhou W; Ilo D; Laroux FS; Deng H; Sanchez Gonzalez Y; Peyrin-Biroulet L
    J Gastroenterol; 2023 Oct; 58(10):990-1002. PubMed ID: 37490069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.